Abstract: Disclosed herein are protocols, isolation means, and compositions of matter useful for identifying mesenchymal stem cells possessing enhanced clinical activity in treatment of autoimmune conditions, such as rheumatoid arthritis (RA). Additionally, markers associated with said enhanced mesenchymal stem cell activity against autoimmunity can be utilized to identify donors whose mesenchymal stem cells possess superior efficacy compared to mesenchymal stem cells from donors who lack said markers associated with said enhanced efficacy in treatment of autoimmunity, such as RA.

Abstract: Disclosed are means, methods and treatments of Leigh Syndrome, using mesenchymal stem cells. In one particular embodiment, mesenchymal stem cells are administered for the purposes of reducing disease progression, and reversing disease. Said mesenchymal stem cells may be generated according to the invention, by selection of markers specifically upregulated or downregulated on enhanced cells as compared to majority of mesenchymal stem cells. The invention further provides means of co-administration of mesenchymal stem cells with lysates, conditioned media, or exosomes of said mesenchymal stem cells to enhance therapeutic activity.

Abstract: Disclosed are means, methods and compositions of matter useful for treatment of spinal muscular atrophy. In one embodiment, stem cells of the mesenchymal type are modified to enhance anti-inflammatory and regenerative potential in a manner to prevent disease, inhibit progression and/or reverse existing disease. In other embodiments combinations of mesenchymal stem cells together with extracts and/or products derived from said mesenchymal stem cells are administered for prevention, inhibition of progression and/or reversion of spinal muscular atrophy.

Abstract: Disclosed are protocols, isolation means, and compositions of matter useful for identifying mesenchymal stem cells possessing enhanced clinical activity. In one embodiment, markers associated with said enhanced mesenchymal stem cell activity are utilized to identify donors whose mesenchymal stem cells possess superior efficacy compared to mesenchymal stem cells from donors who lack said markers associated with said enhanced efficacy. In one embodiment, said markers are utilized to select for mesenchymal stem cells possessing enhanced efficacy from in vitro cultures. In another embodiment, surfaces markers associated with said markers associated with enhanced efficacy are utilized to positively select for cells possessing enhanced efficacy. In another embodiment, the invention teaches markers whose expression is correlated with negative efficacy. Said markers can be utilized to exclude mesenchymal stem cell donors, or in vitro generated and/or isolated mesenchymal stem cells prior to clinical use.

Abstract: Disclosed herein are protocols, isolation means, and compositions of matter useful for identifying mesenchymal stem cells possessing enhanced clinical activity in treatment of autoimmune conditions, such as rheumatoid arthritis (RA). Additionally, markers associated with said enhanced mesenchymal stem cell activity against autoimmunity can be utilized to identify donors whose mesenchymal stem cells possess superior efficacy compared to mesenchymal stem cells from donors who lack said markers associated with said enhanced efficacy in treatment of autoimmunity, such as RA.

Abstract: Disclosed are compositions of matter, protocols, and treatment means for generation of tissues capable of administration in a flowable manner through contain with one or more antibiotics, or derivatives of said antibiotics. In one embodiment the invention provides the treatment of morselized amniotic membranes with antibiotics in a manner as to increase buoyancy of morselized components of said amniotic membranes in order to prevent gravity based accumulation of said morselized tissue. In another embodiment buoyancy of morselized tissue is modulated by contacting said tissue with an antibiotic or derivative thereof in a manner to allow for increased uniformity of said morselized tissue components throughout a vessel. In another embodiment, pancreatic islets are isolated and stored in a manner to prevent gravity based aggregation. The invention pertains to all tissues, with emphasize in a preferred embodiment to tissues which are useful when administered in a flowable manner.

Abstract: The invention discloses means of treating pain through administration of mesenchymal stem cells or derivatives thereof via an intrathecal manner at a concentration and frequency sufficient to reduce pain. In one embodiment of the invention, treatment of discogenic pain is provided by administration of mesenchymal stem cells intrathecally that are derived from the Wharton's Jelly. In another embodiment the invention teaches administration of supernatants from mesenchymal stem cells, in one embodiment said supernatants comprising of concentrated microvesicles.

Abstract: Disclosed are methods, compositions of matter and cells for treatment of cardiovascular disease through concurrent inhibition of oxidative stress while administration of a cell therapy. The invention also concerts the modulation of oxidative stress for preferential induction of differentiation while concurrently inhibiting inflammatory processes that decrease efficacy of cellular therapy.

Abstract: The present invention provides mesenchymal stem cells and mesenchymal-like cells useful for treatment of muscular dystrophies including Duchenne Muscular Dystrophy (DMD), as well as, Becker, limb girdle, congenital, facioscapulohumeral, myotonic, oculopharyngeal, distal, and Emery-Dreifuss dystrophies. Also provided are protocols for administration of cells for treatment of the above dystrophies and adjuvant protocols. Futhermore, the invention teaches methods of manipulating mesenchymal and mesenchymal-like cells in vitro and in vivo for augmentation of therapeutic effects. Particularly, use of endometrial regenerative cells, alone or in combination with mesenchymal stem cells is provided for treatment of DMD and Becker muscular dystrophy.

Abstract: Disclosed are methods, compositions of matter and cells for treatment of cardiovascular disease through concurrent inhibition of oxidative stress while administration of a cell therapy. The invention also concerts the modulation of oxidative stress for preferential induction of differentiation while concurrently inhibiting inflammatory processes that decrease efficacy of cellular therapy.

Abstract: Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and/or indirectly stimulatory of angiogenesis and/or vascular responsiveness. Another aspect provides means of increasing sensitivity to insulin through administration of a cell composition capable of integrating into host insulin responsive tissue and upregulating responsiveness either through mobilization of host cells capable of responding to insulin, mobilization of host cells capable of endowing insulin responsiveness on other host cells, exogenously administered cells taking the role of insulin responsiveness, or exogenously administered cells endowing insulin responsiveness on other host cells.

Abstract: The present invention relates to a composition and method for preventing or reducing edema, deep vein thrombosis (DVT), and/or pulmonary embolism by administering a combination of a fibrinolytic agent and an antioxidant. The composition is particularly useful for treating individuals prior to or during long term flights or other situations involving extended immobility.

Abstract: A method of increasing the growth of stem cells by mixing the stem cells with a growth medium that has been conditioned by an incubation with placental tissue. The method increases the expansion of the stem cell population.